{"artifact":{"id":"rp-ad-apoe-202604280307","artifact_type":"research_plan","entity_ids":"[\"APOE\", \"Alzheimer's disease\"]","title":"AD Research Plan: APOE targeting in Alzheimer's disease","quality_score":0.85,"created_by":"ad_master_plan_synthesizer","provenance_chain":"[]","content_hash":"dd06d2509875d8f2ef35ca66c4c48ad4a05714a76fa8145d2429675b41a7faae","metadata":{"_origin":{"url":null,"type":"internal","tracked_at":"2026-04-28T03:07:54.652169"},"disease":"Alzheimer's disease","cost_usd":983500.0,"timeline":"18-24 months","prereg_id":"7","assay_spec":"Phase 2 RCT comparing APOE modulator vs. placebo in N=300 early AD patients, primary endpoint: change from baseline on composite cognitive score at 18 months. Sample size powered at 80% for effect size=0.38, alpha=0.05.","hypothesis":"APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function","power_calc":{"test":"two-sided t-test","alpha":0.05,"power":0.8,"effect_size":0.38},"sample_size":300,"target_gene":"APOE","kill_criteria":["APOE4→APOE3 conversion shows no amyloid reduction in Phase 3 trial","APOE isoform switching fails to improve cognitive endpoints at 18 months","Lipid代谢 correction fails to modify disease progression in APOE4 carriers"],"_schema_version":1,"primary_endpoint":"Composite cognitive score (ADAS-Cog13 + ADCS-ADL)","upstream_target_id":"ut-ad-apoe-202604280307","identification_strategy":"MR + RCT"},"created_at":"2026-04-27T20:07:54.652250-07:00","updated_at":"2026-04-27T20:07:54.652250-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"80d1c0ef-b787-4e25-a62f-2243525a2e64","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"ad_master_plan_synthesizer"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"ut-ad-apoe-202604280307","link_type":"derives_from","strength":1.0,"evidence":"Research plan tests upstream target ut-ad-apoe-202604280307"}],"incoming_links":[],"current_artifact_id":"rp-ad-apoe-202604280307","is_canonical":true,"supersede_chain":["rp-ad-apoe-202604280307"]}